Equities research analysts expect Neon Therapeutics Inc (NASDAQ:NTGN) to announce ($0.81) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($0.87). Neon Therapeutics posted earnings of ($7.84) per share in the same quarter last year, which would suggest a positive year over year growth rate of 89.7%. The firm is scheduled to report its next quarterly earnings results on Monday, August 5th.
According to Zacks, analysts expect that Neon Therapeutics will report full-year earnings of ($2.69) per share for the current financial year, with EPS estimates ranging from ($3.33) to ($1.83). For the next financial year, analysts forecast that the company will report earnings of ($2.63) per share, with EPS estimates ranging from ($4.26) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.03).
Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new position in Neon Therapeutics during the 1st quarter worth approximately $49,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Neon Therapeutics by 100.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers bought a new position in Neon Therapeutics in the first quarter valued at approximately $78,000. Bank of New York Mellon Corp lifted its stake in Neon Therapeutics by 17.6% in the fourth quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after buying an additional 2,905 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Neon Therapeutics by 42.7% in the fourth quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares in the last quarter. 69.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:NTGN traded down $0.56 during trading on Friday, hitting $3.57. 345,529 shares of the company’s stock were exchanged, compared to its average volume of 191,000. Neon Therapeutics has a 1-year low of $3.49 and a 1-year high of $13.00. The company’s 50-day moving average is $4.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.30 and a current ratio of 7.30. The company has a market capitalization of $117.01 million and a price-to-earnings ratio of -0.64.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Recommended Story: How to Trade Using Analysts Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.